Professor John Mascarenhas Details Breakthrough Safety and Efficacy Data of INCA33989 in Patients with ET丨EHA 2025

Professor John Mascarenhas Details Breakthrough Safety and Efficacy Data of INCA33989 in Patients with ET丨EHA 2025

2025.09.01
The 2025 European Hematology Association (EHA) Annual Meeting was recently held, bringing together top global experts in the field of hematologic malignancies to discuss the latest research findings and future directions. In the highly anticipated "Late-Breaking Abstract" session, Professor John Mascarenhas from the Icahn School of Medicine at Mount Sinai presented clinical study data on INCA33989, a novel, first-in-class monoclonal antibody specific to mutant calreticulin (CALR). The study results showed that INCA33989 demonstrated excellent safety and revolutionary therapeutic potential in previously treated patients with Essential Thrombocythemia (ET), with the potential to change the current treatment landscape
A Trans-Pacific Meeting of Minds: US–China Collaboration in Urology

A Trans-Pacific Meeting of Minds: US–China Collaboration in Urology

2025.08.15
On July 10–11, 2025, Professor Steven Campbell, Chair of Urology at West Virginia University, visited the Sun Yat-sen University Cancer Center (SYSUCC) for a two-day academic exchange. His visit brought an international, cutting-edge perspective to SYSUCC’s Department of Urology while also showcasing the department’s achievements to peers worldwide.
Blood Science Update | Long-Term Outcomes of Cytarabine Use in Pediatric APL: 12-Year Follow-Up of a Randomized Controlled Trial

Blood Science Update | Long-Term Outcomes of Cytarabine Use in Pediatric APL: 12-Year Follow-Up of a Randomized Controlled Trial

2025.08.14
Acute promyelocytic leukemia (APL) is among the most curable forms of pediatric acute myeloid leukemia, primarily due to the success of ATRA and arsenic trioxide (ATO)-based therapies. However, the contribution of cytarabine (Ara-C) to long-term outcomes remains debated. In this newly published study in Blood Science, researchers present the results of a prospective, randomized trial examining the long-term impact of adding Ara-C during consolidation therapy for children with APL.
ASCO Highlights | Prof. Jia Wang: New Five-Year Survival Evidence Supports Chemotherapy De-escalation in HER2-Positive Early Breast Cancer — Summary of Three WSG Trials Including ADAPT

ASCO Highlights | Prof. Jia Wang: New Five-Year Survival Evidence Supports Chemotherapy De-escalation in HER2-Positive Early Breast Cancer — Summary of Three WSG Trials Including ADAPT

2025.08.05
At the 2025 ASCO Annual Meeting, the West German Study Group (WSG) presented a pooled analysis (Abstract No. 502) of three trials—including the ADAPT TP study—exploring survival outcomes following chemotherapy de-escalation in HER2-positive early breast cancer (eBC). Oncology Frontier invited Prof. Jia Wang and Dr. Jinze Yu from the Second Affiliated Hospital of Dalian Medical University to interpret and comment on the findings for our readers.
BOC/BOA 2025 Preview | Prof. Jinming Yu: A Decade of Progress Elevates China’s Fight Against Cancer—Uniting Global Wisdom for a New Journey Ahead

BOC/BOA 2025 Preview | Prof. Jinming Yu: A Decade of Progress Elevates China’s Fight Against Cancer—Uniting Global Wisdom for a New Journey Ahead

2025.08.04
The 2025 Annual Conference of the Chinese Society of Clinical Oncology (BOC) and Best of ASCO® 2025 China (BOC/BOA) will be held on July 4–5 in Nanjing. This year’s event coincides with the 10th anniversary of the China Clinical Oncology Annual Research Progress publication—marking a key milestone in China's oncology journey. Over the past decade, the field has witnessed robust growth, and BOC/BOA has emerged as a vital academic bridge linking global innovations with local practice. This year’s conference will bring together leading experts from around the world to review the remarkable achievements of the past ten years and explore future directions in cancer care.